Volume 18, Issue 1 (March-2026 2026)                   Iranian Journal of Blood and Cancer 2026, 18(1): 138-149 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Neamah A S, Khavaninzadeh N, Bonakdar A, Haj Mohammadi Z, Hosseinzadeh S. Significance of Heat Shock Proteins on Hyperthermia-based Therapeutics. Iranian Journal of Blood and Cancer 2026; 18 (1) :138-149
URL: http://ijbc.ir/article-1-1880-en.html
Significance of Heat Shock Proteins on Hyperthermia-based Therapeutics
Alaa Sameer Neamah1 , Nima Khavaninzadeh2 , Ali Bonakdar3 , Zeynab Haj Mohammadi4 , Simzar Hosseinzadeh *5
1- College of Nursing, University of Dhi Qar, Dhi Qar, Irag
2- Department of Industrial and Environmental Biotechnology, National Institute for Genetic Engineering and Biotechnology NIGEB, Tehran, Iran.
3- Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
5- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. & Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 1968917313. , s.hosseinzadeh@sbmu.ac.ir
Abstract:   (118 Views)
Numerous studies have shown that combining hyperthermia (HT) with other breast cancer treatment strategies can yield beneficial outcomes. Research indicates that HT may enhance tumor reduction, improve local tumor control, and potentially contribute to increased survival rates. Nonetheless, further investigations are essential to fully elucidate its therapeutic advantages and to establish the most effective protocols for its integration into breast cancer care. In response to hyper thermic stress, the body activates protective mechanisms, notably the upregulation of heat shock proteins (HSPs). These proteins help mitigate cellular damage and dysfunction by enabling cells to better withstand elevated temperatures. As such, understanding the behavior of HSPs under hyper thermic conditions is a vital area of research for exploring how cells cope with thermal stress and for identifying novel therapeutic targets. HSPs represent a conserved group of proteins present in both prokaryotic and eukaryotic cells. They are essential for maintaining protein homeostasis (proteostasis) and safeguarding cells from various stressors. Classified by molecular weight, HSPs act as molecular chaperones, facilitating the folding of newly synthesized polypeptides, refolding misfolded proteins, assembling multi-protein complexes, and degrading damaged proteins. In addition to their chaperone activity, HSPs play key roles in cellular signaling pathways, regulation of the cell cycle, and the initiation of apoptosis.
Keywords: Hyperthermia, Breast cancer, Clinical trials, Nanoparticles, Anticancer drugs
Full-Text [PDF 1709 kb]   (107 Downloads)    
: Review Article | Subject: Radiotherapy
Received: 2026/02/24 | Accepted: 2026/03/8 | Published: 2026/03/30
References
1. Buttacavoli, M., et al., Prognostic and functional significant of heat shock proteins (HSPs) in breast cancer unveiled by multi-omics approaches. Biology, 2021. 10(3): p. 247. [DOI:10.3390/biology10030247]
2. Hatamie, S., et al., HT of breast cancer tumor using graphene oxide-cobalt ferrite magnetic nanoparticles in mice. Journal of Drug Delivery Science and Technology, 2021. 65: p. 102680. [DOI:10.1016/j.jddst.2021.102680]
3. Medina, M.A., et al., Synthesis, characterization and magnetic HT of monodispersed cobalt ferrite nanoparticles for cancer therapeutics. Molecules, 2020. 25(19): p. 4428. [DOI:10.3390/molecules25194428]
4. Ahmed, K., et al., HT and protein homeostasis: Cytoprotection and cell death. Journal of thermal biology, 2020. 91: p. 102615. [DOI:10.1016/j.jtherbio.2020.102615]
5. Richter, K., M. Haslbeck, and J. Buchner, The heat shock response: life on the verge of death. Molecular cell, 2010. 40(2): p. 253-266. [DOI:10.1016/j.molcel.2010.10.006]
6. Rezanezhad, A., et al., Superparamagnetic magnetite nanoparticles for cancer cells treatment via magnetic HT: effect of natural capping agent, particle size and concentration. Journal of Materials Science: Materials in Electronics, 2021. 32(19): p. 24026-24040. [DOI:10.1007/s10854-021-06865-8]
7. Kaur, P., et al., HT using nanoparticles-promises and pitfalls. International Journal of HT, 2016. 32(1): p. 76-88. [DOI:10.3109/02656736.2015.1120889]
8. Chatterjee, S. and T.F. Burns, Targeting heat shock proteins in cancer: a promising therapeutic approach. International journal of molecular sciences, 2017. 18(9): p. 1978. [DOI:10.3390/ijms18091978]
9. Hu, C., et al., Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities. MedComm, 2022. 3(3): p. e161. [DOI:10.1002/mco2.161]
10. Liu, X., et al., Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2023. 1878(6): p. 189013. [DOI:10.1016/j.bbcan.2023.189013]
11. Ma, X., et al., Fe 3 O 4-Pd Janus nanoparticles with amplified dual-mode HT and enhanced ROS generation for breast cancer treatment. Nanoscale Horizons, 2019. 4(6): p. 1450-1459. [DOI:10.1039/C9NH00233B]
12. Moros, M., et al., Triggering antitumoural drug release and gene expression by magnetic HT. Advanced drug delivery reviews, 2019. 138: p. 326-343. [DOI:10.1016/j.addr.2018.10.004]
13. Chang, M., et al., Recent advances in HT therapy‐based synergistic immunotherapy. Advanced Materials, 2021. 33(4): p. 2004788. [DOI:10.1002/adma.202004788]
14. Qiao, K., et al., Novel reduction of hysteresis loss controlled by strain memory effect in FeRh/PMN-PT heterostructures. Nano Energy, 2019. 59: p. 285-294. [DOI:10.1016/j.nanoen.2019.02.044]
15. Liu, X., et al., Comprehensive understanding of magnetic HT for improving antitumor therapeutic efficacy. Theranostics, 2020. 10(8): p. 3793. [DOI:10.7150/thno.40805]
16. Chandrasekharan, P., et al., Using magnetic particle imaging systems to localize and guide magnetic HT treatment: tracers, hardware, and future medical applications. Theranostics, 2020. 10(7): p. 2965. [DOI:10.7150/thno.40858]
17. Mohapatra, S., T.A. Nguyen, and P. Nguyen-Tri, Noble metal-metal oxide hybrid nanoparticles: Fundamentals and applications. 2018: Elsevier.
18. Yagawa, Y., et al., Cancer immunity and therapy using HT with immunotherapy, radiotherapy, chemotherapy, and surgery. J. Cancer Metastasis Treat, 2017. 3(10): p. 218. [DOI:10.20517/2394-4722.2017.35]
19. Mantso, T., et al. Effects of HT as a mitigation strategy in DNA damage-based cancer therapies. in Seminars in cancer biology. 2016. Elsevier. [DOI:10.1016/j.semcancer.2016.03.004]
20. Dunne, M., M. Regenold, and C. Allen, HT can alter tumor physiology and improve chemo-and radio-therapy efficacy. Advanced Drug Delivery Reviews, 2020. 163: p. 98-124. [DOI:10.1016/j.addr.2020.07.007]
21. Vujaskovic, Z., et al., A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and HT in locally advanced breast cancer. International Journal of HT, 2010. 26(5): p. 514-521. [DOI:10.3109/02656731003639364]
22. De Cuba, E., et al., Angiogenesis-related markers and prognosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Annals of surgical oncology, 2016. 23(5): p. 1601-1608. [DOI:10.1245/s10434-015-5023-0]
23. Datta, N.R., et al., HT and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. International Journal of Radiation Oncology* Biology* Physics, 2016. 94(5): p. 1073-1087. [DOI:10.1016/j.ijrobp.2015.12.361]
24. Singh, V., et al., Quantifying DNA damage induced by ionizing radiation and HT using single DNA molecule imaging. Translational oncology, 2020. 13(10): p. 100822. [DOI:10.1016/j.tranon.2020.100822]
25. Elming, P.B., et al., HT: the optimal treatment to overcome radiation resistant hypoxia. Cancers, 2019. 11(1): p. 60. [DOI:10.3390/cancers11010060]
26. Moghaddam, F.F., et al., Clinical effectiveness of combined whole body HT and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. Journal of Thermal Biology, 2024. 120: p. 103804. [DOI:10.1016/j.jtherbio.2024.103804]
27. Refaat, T., et al., HT and radiation therapy for locally advanced or recurrent breast cancer. The Breast, 2015. 24(4): p. 418-425. [DOI:10.1016/j.breast.2015.03.008]
28. Van Rhoon, G., M. Franckena, and T. Ten Hagen, A moderate thermal dose is sufficient for effective free and TSL based thermochemotherapy. Advanced Drug Delivery Reviews, 2020. 163: p. 145-156. [DOI:10.1016/j.addr.2020.03.006]
29. Mohamed, F., et al., Thermal enhancement of new chemotherapeutic agents at moderate HT. Annals of surgical oncology, 2003. 10(4): p. 463-468. [DOI:10.1245/ASO.2003.08.006]
30. Huang, C., et al., Synergistic effect of HT and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011. 31(4): p. 488-496. [DOI:10.1007/s11596-011-0478-0]
31. Procopio, N., Proteome Taphonomy: Biomolecular Investigations into the Process of Decay for Forensic and Archaeological Applications. 2018: The University of Manchester (United Kingdom).
32. Garden, A.S. 31. Evaluation of Pain and Difficulty Swallowing Associated with Oral Mucositis during Radiation for Head and Neck Cancers. in The Cancer Journal. 2003. LWW. [DOI:10.1097/00130404-200311000-00034]
33. Conte, E., A. Psihogios, and D. Seely, HT in cancer care: a literature review. CAND Journal, 2021. 28(3): p. 14-30. [DOI:10.54434/candj.92]
34. Day, E.S., J.G. Morton, and J.L. West, Nanoparticles for thermal cancer therapy. 2009. [DOI:10.1115/1.3156800]
35. Hand, J.W., et al., Methods of external hyperthermic heating. 2012: Springer Science & Business Media.
36. Habash, R.W., Therapeutic HT. Handbook of clinical neurology, 2018. 157: p. 853-868. [DOI:10.1016/B978-0-444-64074-1.00053-7]
37. Notter, M., et al., Recommendation of regional HT in the treatment of breast cancer. Integrative Cancer Therapies, 2021. 20: p. 1534735420988606. [DOI:10.1177/1534735420988606]
38. Saim, H., et al., RETRACTED ARTICLE: Antitumor effect of infrared whole-body HT with curcumin in breast Cancer. Multimedia Tools and Applications, 2022. 81(29): p. 41851-41868. [DOI:10.1007/s11042-022-13521-8]
39. Phillips, J.L., A topical review of magnetic fluid HT. Journal of Science and Health at the University of Alabama, 2005. 3: p. 14-18.
40. Cepeda, M., et al. ADVANCED COMPUTER MODELING FOR INTERSTITIAL MICROWAVE HT THERAPY-Comparison of Two Numerical Methods in Computational Electromagnetics. in International Conference on Biomedical Electronics and Devices. 2010. SCITEPRESS.
41. Issels, R.D., et al., Effect of neoadjuvant chemotherapy plus regional HT on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA oncology, 2018. 4(4): p. 483-492. [DOI:10.1001/jamaoncol.2017.4996]
42. Feyerabend, T., et al., Local HT, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease. International Journal of Radiation Oncology* Biology* Physics, 2001. 49(5): p. 1317-1325. [DOI:10.1016/S0360-3016(00)01514-5]
43. Scott, R.S., et al., Local HT in combination with definitive radiotherapy: Increased tumor clearance, reduced recurrence rate in extended follow-up. International Journal of Radiation Oncology* Biology* Physics, 1984. 10(11): p. 2119-2123. [DOI:10.1016/0360-3016(84)90211-6]
44. Liu, J.F., et al., Use of magnetic fields and nanoparticles to trigger drug release and improve tumor targeting. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2019. 11(6): p. e1571. [DOI:10.1002/wnan.1571]
45. Terentyuk, G.S., et al., Laser-induced tissue HT mediated by gold nanoparticles: toward cancer phototherapy. Journal of biomedical optics, 2009. 14(2): p. 021016-021016-9. [DOI:10.1117/1.3122371]
46. Petryk, A.A., et al., Magnetic nanoparticle HT enhancement of cisplatin chemotherapy cancer treatment. International Journal of HT, 2013. 29(8): p. 845-851. [DOI:10.3109/02656736.2013.825014]
47. Mortezaee, K., et al., Synergic effects of nanoparticles-mediated HT in radiotherapy/chemotherapy of cancer. Life sciences, 2021. 269: p. 119020. [DOI:10.1016/j.lfs.2021.119020]
48. Malviya, N., et al., Smart biodegradable polymeric nanoparticles: synthesis, characterization, and applications, in Advancements in controlled drug delivery systems. 2022, IGI Global Scientific Publishing. p. 257-280. [DOI:10.4018/978-1-7998-8908-3.ch011]
49. Kossatz, S., et al., Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic HT and anti-cancer drug delivery. Breast Cancer Research, 2015. 17(1): p. 66. [DOI:10.1186/s13058-015-0576-1]
50. Kandasamy, G., et al., Functionalized hydrophilic superparamagnetic iron oxide nanoparticles for magnetic fluid HT application in liver cancer treatment. ACS omega, 2018. 3(4): p. 3991-4005. [DOI:10.1021/acsomega.8b00207]
51. Tansi, F.L., et al., Effect of matrix-modulating enzymes on the cellular uptake of magnetic nanoparticles and on magnetic HT treatment of pancreatic cancer models in vivo. Nanomaterials, 2021. 11(2): p. 438. [DOI:10.3390/nano11020438]
52. Kawai, N., et al., Effect of heat therapy using magnetic nanoparticles conjugated with cationic liposomes on prostate tumor in bone. The Prostate, 2008. 68(7): p. 784-792. [DOI:10.1002/pros.20740]
53. Sarkar, S. and N. Levi, Variable molecular weight polymer nanoparticles for detection and HT-induced chemotherapy of colorectal cancer. Cancers, 2021. 13(17): p. 4472. [DOI:10.3390/cancers13174472]
54. Scutigliani, E.M., et al., Modulating the heat stress response to improve HT-based anticancer treatments. Cancers, 2021. 13(6): p. 1243. [DOI:10.3390/cancers13061243]
55. Yi, G.Y., et al., HT treatment as a promising anti-cancer strategy: therapeutic targets, perspective mechanisms and synergistic combinations in experimental approaches. Antioxidants, 2022. 11(4): p. 625. [DOI:10.3390/antiox11040625]
56. Kuo, I.-M., et al., Potential enhancement of host immunity and anti-tumor efficacy of nanoscale curcumin and resveratrol in colorectal cancers by modulated electro-HT. BMC cancer, 2020. 20(1): p. 603. [DOI:10.1186/s12885-020-07072-0]
57. Zhang, X., et al., Quercetin enhanced paclitaxel therapeutic effects towards PC-3 prostate cancer through ER stress induction and ROS production. OncoTargets and therapy, 2020: p. 513-523. [DOI:10.2147/OTT.S228453]
58. Shen, J., et al., The synergistic reversal effect of multidrug resistance by quercetin and HT in doxorubicin-resistant human myelogenous leukemia cells. International journal of HT, 2008. 24(2): p. 151-159. [DOI:10.1080/02656730701843109]
59. Maugeri, A., et al., Targets involved in the anti-cancer activity of quercetin in breast, colorectal and liver neoplasms. International journal of molecular sciences, 2023. 24(3): p. 2952. [DOI:10.3390/ijms24032952]
60. Prossnitz, E.R. and M. Barton, The G-protein-coupled estrogen receptor GPER in health and disease. Nature Reviews Endocrinology, 2011. 7(12): p. 715-726. [DOI:10.1038/nrendo.2011.122]
61. Kalabay, M., et al., Investigation of the antitumor effects of tamoxifen and its ferrocene-linked derivatives on pancreatic and breast cancer cell lines. Pharmaceuticals, 2022. 15(3): p. 314. [DOI:10.3390/ph15030314]
62. Piantelli, M., et al., Quercetin and tamoxifen sensitize human melanoma cells to HT. Melanoma research, 2001. 11(5): p. 469-476. [DOI:10.1097/00008390-200110000-00005]
63. Xu, Z., et al., Naringenin and quercetin exert contradictory cytoprotective and cytotoxic effects on tamoxifen-induced apoptosis in HepG2 cells. Nutrients, 2022. 14(24): p. 5394. [DOI:10.3390/nu14245394]
64. Kawai, N., et al., Safety of regional 8-mhz radiofrequency capacitive HT combined with magnetic cationic liposomes in patients with castration-resistant prostate cancer: A phase i clinical study. J Int Transl Med, 2016. 4(4): p. 258-267.
65. Hafström, L., et al., Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. Journal of clinical oncology, 1991. 9(12): p. 2091-2094. [DOI:10.1200/JCO.1991.9.12.2091]
66. Gazeau, F., M. Lévy, and C. Wilhelm, Optimizing magnetic nanoparticle design for nanothermotherapy. Nanomedicine, 2008. 3(6): p. 831-844. [DOI:10.2217/17435889.3.6.831]
67. Liu, D., et al., Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined HT and chemotherapy. Theranostics, 2020. 10(3): p. 1181. [DOI:10.7150/thno.38989]
68. Espinosa, A., et al., Magnetic (hyper) thermia or photothermia? Progressive comparison of iron oxide and gold nanoparticles heating in water, in cells, and in vivo. Advanced Functional Materials, 2018. 28(37): p. 1803660. [DOI:10.1002/adfm.201803660]
69. Inc, S.N., Intratumoral Targeted HT Therapy (THT) for Cutaneous Metastatic Melanoma. 2025.
70. Slawomir Michalak, P.U.o.M.S., NanoTherm In Adjuvant Therapy of Glioblastoma Multiforme (ANCHIALE). 2024.
71. Cornelius A. Thiels, M.C.R.P., Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis. 2024.
72. Gautam, A. and F.C. van Veggel, Synthesis of nanoparticles, their biocompatibility, and toxicity behavior for biomedical applications. Journal of Materials Chemistry B, 2013. 1(39): p. 5186-5200. [DOI:10.1039/c3tb20738b]
73. Soeiro, J.F., et al., Advances in screening hyperthermic nanomedicines in 3D tumor models. Nanoscale Horizons, 2024. 9(3): p. 334-364. [DOI:10.1039/D3NH00305A]
74. Oehler, J.B., W. Rajapaksha, and H. Albrecht, Emerging applications of nanoparticles in the diagnosis and treatment of breast cancer. Journal of personalized medicine, 2024. 14(7): p. 723. [DOI:10.3390/jpm14070723]
75. Yang, W., et al., Heat shock protein inhibitor, quercetin, as a novel adjuvant agent to improve radiofrequency ablation-induced tumor destruction and its molecular mechanism. Chinese journal of cancer research, 2016. 28(1): p. 19.
76. Mobaraki, F., et al., Synergistic effect of quercetin and cobalt ferrite-graphene oxide-based HT to inhibit expression of heat shock proteins and induce apoptosis in breast cancer cells. Pharmaceutical Sciences, 2022. 28(4): p. 552-563. [DOI:10.34172/PS.2022.6]
77. National Health Research Institutes, T.R.P., A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients. 2015.
78. F. Stephen Hodi, M., Dana-Farber Cancer Institute (Responsible Party), STA-9090(Ganetespib) in Metastatic Ocular Melanoma. 2018.
79. Dana Cardin, M., Vanderbilt-Ingram Cancer Center (Responsible Party), PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer. 2014.
80. C.P. Schroder, U.M.C.G.R.P., Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET). 2012.
81. Party), N.N.P.R., PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer. 2020.
82. Gavilán, H., et al., Magnetic nanoparticles and clusters for magnetic HT: optimizing their heat performance and developing combinatorial therapies to tackle cancer. Chemical Society Reviews, 2021. 50(20): p. 11614-11667. [DOI:10.1039/D1CS00427A]
83. Lörincz, A. Application of the ultrasound HT model for a multi-layered tissue system. in Journal of Physics: Conference Series. 2004. IOP Publishing. [DOI:10.1088/1742-6596/1/1/049]
84. Zhang, Y., et al., Amplifying cancer treatment: advances in tumor immunotherapy and nanoparticle-based HT. Frontiers in Immunology, 2023. 14: p. 1258786. [DOI:10.3389/fimmu.2023.1258786]
85. Labavić, D., et al., Mammalian cell sensitivity to HT in various cell lines: a new universal and predictive description. International Journal of HT, 2020. 37(1): p. 506-516. [DOI:10.1080/02656736.2020.1762005]
86. Sethi, M. and S. Chakarvarti, HT techniques for cancer treatment: A review. Int. J. PharmTech Res, 2015. 8(6): p. 292-299.
87. Jha, S., P.K. Sharma, and R. Malviya, HT: role and risk factor for cancer treatment. Achievements in the life sciences, 2016. 10(2): p. 161-167. [DOI:10.1016/j.als.2016.11.004]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb